噻托溴铵联合布地奈德吸入治疗对哮喘-慢阻肺重叠综合征患者肺功能和睡眠质量的影响

doi:10.3969/j.issn.1006-6233.2024.08.014

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1250 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the effect of tiotropium bromide combined with budesonide inhalation therapy on lung function and sleep quality in patients with asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).Methods: A total of 98 ACOS patients treated in our hospital from January 2019 to January 2024 were sampled. They were divided into two groups using the random number table method, with 49 cases in each group. The control group was treated with budesonide inhalation, and the observation group was treated with tiotropium bromide based on the control group. Both groups were treated for 3 months. The two groups of patients were compared before and after treatment in terms of inflammation levels [interleukin 6 (IL - 6), tumor necrosis factor alpha (TNF alpha), hypersensitive c-reactive protein (hs - CRP)], immune function [17 (Th17 and regulatory T helper T cells , of Th17 / Treg cells (Treg)], airway remodeling factor [transforming growth factor beta 1 - (TGF β1) and osteopontin (OPN) and matrix metalloproteinases 9 (MMP 9)], lung function (forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), and the largest independent ventilation per minute (MVV). Chronic obstructive pulmonary disease (CAT) score and asthma symptom score (ACT) were used to evaluate the disease symptoms before and after treatment, and Pittsburgh Sleep Quality Index (PSQI) scale was used to compare the sleep quality of the two groups after 3 months of treatment.Results: Before treatment, there were no significant differences in serum inflammatory factors, Th17, Th17/Treg, airway remodeling factors, lung function, CAT, and PSQI scores between the two groups (P>0.05). Compared with before treatment, the serum IL-6, TNF-α, hs-CRP, Th17, Th17/Treg, TGF-β1, OPN, MMP-9 levels, ACT and CAT scores in both groups were decreased after treatment, while Treg level, lung function FEV1, FVC, and MVV levels were increased. The difference was statistically significant(P<0.05). There were statistically significant differences in serum inflammatory factors, Th17, Th17/Treg, airway remodeling factors, lung function, CAT, and PSQI scores before and after treatment between the two groups (P<0.05). The sleep status of the observation group after treatment was better than that of the control group, and the difference was statistically significant (P<0.05).Conclusion: The combination of tiotropium and budesonide in the treatment of ACOS helps improve lung function and sleep quality.

Key words： Tiotropium Budesonide Asthma obstructive pulmonary disease overlap syndrome Pulmonary function Quality of sleep

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Baolan
	WANG Liang
	MA Ting

Cite this article:

WANG Baolan,WANG Liang,MA Ting. Effect of Tiotropium Bromide Combined with Budesonide Inhalation Therapy on Lung Function and Sleep Quality in Patients with Asthma-Colonial Overlap Syndrome[J]. HeBei Med, 2024, 30(8): 1309-1315.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.08.014 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I8/1309

[1] 何权瀛.哮喘-慢阻肺重叠综合征的诊断和治疗以及管理一事的由来和结局[J].中国呼吸与危重监护杂志,2021,20(1):1-3.
[2] Chen YC,Chang YP,Huang KT,et al.Unraveling the pathogenesis of asthma and chronic obstructive pulmonary disease overlap: focusing on epigenetic mechanisms[J].Cells,2022,11(11):1728.
[3] 彭昊,龙博文,钟炜,等.支气管哮喘患儿CHI3L1基因多态性与糖皮质激素疗效的关系研究[J].中国现代医学杂志,2021,31(3):24-30.
[4] 罗观,苏继鲁,包海荣.布地奈德联合噻托溴铵治疗支气管哮喘的临床研究[J].中国临床药理学杂志,2021,37(4):366-369.
[5] 孙永昌.哮喘-慢阻肺重叠综合征指南解读[J].中国呼吸与危重监护杂志,2014,13(4):325-329.
[6] Ishiura Y,Fujimura M,Ohkura N,et al.Triple therapy with budesonide/glycopyrrolate/formoterol fumarate improves inspiratory capacity in patients with asthma-chronic obstructive pulmonary disease overlap[J].Int Chron Obstruct Pulmon Dis,2020(15):269-277.
[7] Arslan B,Cetin GP,Yilmazi.The role of long-acting antimuscarinic agents in the treatment of asthma[J].Aerosol Med Pulm Drug Deliv,2023,36(4):189-209.
[8] Zhao L,Chen Z,Cheng J,et al.Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats[J].Pulm Pharmacol Ther,2023(80):102215.
[9] Fuentes N,McCullough M,Panettieri RA Jr,et al.RGS proteins,GRKs,and beta-arrestins modulate G protein-mediated signaling pathways in asthma[J].Pharmacol Ther,2021(223):107818.
[10] Calzetta L,Ritondo BL,Zappa MC,et al.The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review[J].Eur Respir Rev,2022,31(164):210196.
[11] Frey A,Lunding LP,Ehlers JC,et al.More than just a barrier: the immune functions of the airway epithelium in asthma pathogenesis[J].Front Immunol,2020(11):761.
[12] He BX,Fang SB,Xie YC,et al.Small extracellular vesicles derived from human mesenchymal stem cells prevent Th17-dominant neutrophilic airway inflammation via immunoregulation on Th17 cells[J].Int Immunopharmacol,2024(133):112126.
[13] Zheng R,Wang F,Huang Y,et al.Elevated Th17 cell frequencies and Th17/Treg ratio are associated with airway hyperresponsiveness in asthmatic children[J].Asthma,2021,58(6):707-716.
[14] Jiang T,Li P,Wang Y.Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma-COPD overlap syndrome[J].Allergol Immunopathol (Madr),2023,51(4):131-138.
[15] Akurugu WA,Van Heerden CJ,Mulder N,et al.Hypothalamic-pituitary-adrenal axis suppression in asthma: a glucocorticoid receptor polymorphism may protect[J].Pediatr Allergy Immunol,2021,32(2):273-279.
[16] Shi ZL,Zhang HY,Peng HB,et al.Tiotropium in patients with bronchiectasis: a prospective cohort study[J].Lung,2023,201(1):9-15.